| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PSG9 |
| Uniprot No | Q00887 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 35-426aa |
| 氨基酸序列 | EVTIEAQPPKVSEGKDVLLLVHNLPQNLPGYFWYKGEMTDLYHYIISYIV DGKIIIYGPAYSGRETVYSNASLLIQNVTRKDAGTYTLHIIKRGDETREE IRHFTFTLYLETPKPYISSSNLNPREAMEAVRLICDPETLDASYLWWMNG QSLPVTHRLQLSKTNRTLYLFGVTKYIAGPYECEIRNPVSASRSDPVTLN LLPKLPIPYITINNLNPRENKDVLAFTCEPKSENYTYIWWLNGQSLPVSP GVKRPIENRILILPSVTRNETGPYQCEIQDRYGGLRSNPVILNVLYGPDL PRIYPSFTYYRSGENLDLSCFTESNPPAEYFWTINGKFQQSGQKLFIPQI TRNHSGLYACSVHNSATGKEISKSMTVKVSGPCHGDLTESQS |
| 预测分子量 | 69 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PSG9重组蛋白的模拟参考文献示例(仅供参考，建议通过学术数据库验证具体内容)：
---
1. **标题**: *Recombinant PSG9 Protein Expression and Immunomodulatory Function*
**作者**: Smith A, et al.
**摘要**: 研究报道了在HEK293细胞中成功表达并纯化重组PSG9蛋白，证实其通过调控TGF-β信号通路抑制母体免疫反应，可能在妊娠早期胎儿耐受中发挥作用。
2. **标题**: *Structural Characterization of PSG9 and Its Interaction with CD1d*
**作者**: Lee B, et al.
**摘要**: 通过X射线晶体学解析了PSG9的胞外结构域，发现其与CD1d分子特异性结合，提示其在抗原呈递和自然杀伤细胞(NK细胞)调节中的潜在机制。
3. **标题**: *PSG9 as a Potential Biomarker in Preeclampsia*
**作者**: Zhang Y, et al.
**摘要**: 分析孕妇血清发现PSG9水平与子痫前期风险呈负相关，重组PSG9在体外实验中显示可抑制血管内皮炎症反应，为疾病治疗提供新靶点。
4. **标题**: *PSG9 Recombinant Protein Enhances Trophoblast Invasion via Integrin Binding*
**作者**: Gupta R, et al.
**摘要**: 研究证实重组PSG9通过结合整合素α5β1促进滋养层细胞侵袭和胎盘形成，为阐明妊娠相关并发症的分子机制提供依据。
---
**注意**：以上文献信息为模拟示例，实际研究需通过PubMed、Web of Science等平台检索。PSG9(Pregnancy-Specific Glycoprotein 9)的研究多聚焦于妊娠免疫调节、肿瘤微环境等领域，建议结合具体研究方向筛选文献。
**Background of PSG9 Recombinant Protein**
Pregnancy-specific glycoprotein 9 (PSG9), a member of the human pregnancy-specific glycoprotein (PSG) family, is primarily expressed in the placenta during pregnancy. PSGs belong to the carcinoembryonic antigen (CEA) gene family, which plays roles in cell adhesion, immune modulation, and fetal-maternal communication. PSG9. encoded by the *PSG9* gene, is a secreted protein characterized by its immunoglobulin-like domains and heavy glycosylation. It is implicated in promoting maternal immune tolerance to the semi-allogeneic fetus by interacting with receptors on immune cells, such as dendritic cells and macrophages, to induce anti-inflammatory cytokine secretion.
Recombinant PSG9 is produced using expression systems like mammalian cells (e.g., HEK293 or CHO cells) to ensure proper post-translational modifications, including glycosylation, which is critical for its biological activity. The protein is purified via affinity chromatography, often tagged with markers like His or Fc for detection and isolation.
Research on PSG9 focuses on its role in pregnancy maintenance, particularly in modulating immune responses and trophoblast function. Dysregulation of PSG9 has been linked to pregnancy complications, such as preeclampsia and intrauterine growth restriction. Beyond reproductive health, PSG9 is studied in cancer due to its structural similarity to CEACAM proteins, which are associated with tumor progression and immune evasion.
As a recombinant tool, PSG9 aids in elucidating mechanisms of fetal-maternal tolerance and developing diagnostic or therapeutic strategies for pregnancy disorders. Its potential applications extend to immunotherapy, where engineered PSG9 variants might regulate immune pathways in autoimmune diseases or cancer.
In summary, PSG9 recombinant protein serves as a vital resource for understanding placental biology, immune modulation, and disease pathogenesis, bridging translational research in obstetrics and oncology.
×
